It is estimated that less than 10% of drug development programmes result in safe and efficacious therapies. This congress brings together a host of drug development experts to discuss how we can strengthen the link between innovative science and clinical success.
Day One of the congress covers key advances in predictive science, such as stem cell technologies for predictive modeling and novel biomarker technology for safety prediction. Speakers will discuss methods of achieving physiologically relevant models and compare strategies for tackling predictive challenges, such as complex biologics and multi-target drugs.
Day Two of the congress looks at the way translational research can unlock the potential of early stage pipelines. Presentations will explore ways of harmonising ADMET strategy in discovery and development, integrating toxicology practices throughout the pipeline and improving the use of imaging in translational research. Delegates will also hear case studies concerning key tools for translational medicine, including novel immunoassays, resistance biomarkers and quantitative science applications.
The congress is part of the 15th Annual Drug Discovery Summit – Europe’s premier networking and discussion forum for pharmaceutical leaders. The congress is also co-located with the 2nd Annual Discovery Chemistry and Drug Design Congress 2014.
Day 1: Predictive Science
- Stem cell technology for effective predictive modeling
- Immunogenicity prediction and mitigation
- Predictive biomarkers: development and validation
- IVIVCS: bridging the gap between in vitro and in vivo
- Safety prediction: novel biomarker technology, genetic variation studies
- Predictive science in co-medication research
- Exploratory toxicology and mechanism based toxicity testing
- Predictive challenges: complex biologics and multi-target action
Day 2: Translational Medicine
- The role of imaging technology in translational medicine
- Harmonising ADMET strategy in discovery and development
- Integrating toxicology practices throughout the pipeline
- New tools for translational medicine: novel immunoassays, resistance biomarkers, toxicogenomic applications
- PK/PD – improving decision making from candidate selection to clinical trial
- Quantitative science: the building block of translational medicine?
- Philip M. Arlen – President & CEO, Precision Biologics
- Joerg Bluemel – Director Biologics Safety Assessment, Translational Sciences, MedImmune
- Roberta Bursi – Senior Director Global Biometrics, Head of Pharmacometrics, Grünenthal
- Donna Dambach – Director, Director, Small Molecule & Investigative Toxicology, Genentech
- Hugues Dolgos – Senior Director, Global Early Development, Translational Medicine Strategy Implementation Leader, Merck Serono
- Pamela Garzone – Executive Director Biotechnology Clinical Research, Pfizer
- Manfred Kansy – Head Science and Technology Strategy in Non-Clinical Safety, Roche
- Stephan Kirchner – Head Discovery Genotoxicity and In Vitro Phototoxicity, Roche
- Thierry Lave – Head DMPK Modeling and Simulation, Roche
- Magnus Ord – Global Section Director Safety Science, AstraZeneca
- Vito Sasseville – Executive Director, Preclinical Safety: Discovery & Investigative Safety, Novartis
Submit a poster
For attendees interested in submitting a poster, there are opportunities now available. Your poster presentation will be located in the exhibition room for two days alongside other posters from senior scientists working in industry and academia.
How to submit your poster
We will require:
- Poster title, Abstract (200 words or less)
- Principal author, Organisation
- Mailing address, Email, Telephone, Fax
- Additional authors
In order to secure your board space a fee of £125 will be required. The poster should be presented as A0 (841mm x 1189mm) portrait size.
To take advantage of this opportunity you need to be registered as a paid delegate over the 2 days. We have limited spaces available,so please register soon!
Who Will Attend
The 6th Annual Drug Development Congress is an exclusive event designed for senior level attendees from leading pharmaceutical and biotechnology organisations, along with highly esteemed members of academic and government institutions.
Delegates typically include VPs, Directors and Global Heads of:
- Assay development
- Modeling & simulation
- Predictive science
- Research & development
- Translational medicine
Delegates will benefit from…
- An executive format that facilitates idea exchange and discussion of relevant experiences through case study presentations and strategic discussions
- Networking opportunities and knowledge share with highly-esteemed peers
- Pre-scheduled one-to-one meetings with solution providers offering an opportunity to forge partnerships and discover innovative solutions
- Post event follow up providing all documentation from the meeting and re-booking discounts
- Tailor-made agenda – hand pick any conference and panel sessions you wish to attend